Raphas Co. Ltd (214260) - Total Assets
Based on the latest financial reports, Raphas Co. Ltd (214260) holds total assets worth ₩72.26 Billion KRW (≈ $48.97 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 214260 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Raphas Co. Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Raphas Co. Ltd's total assets have evolved over time, based on quarterly financial data. See 214260 net asset value for net asset value and shareholders' equity analysis.
Raphas Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Raphas Co. Ltd's total assets of ₩72.26 Billion consist of 47.1% current assets and 52.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 20.4% |
| Accounts Receivable | ₩3.16 Billion | 4.2% |
| Inventory | ₩5.22 Billion | 7.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.78 Billion | 3.7% |
| Goodwill | ₩1.35 Billion | 1.8% |
Asset Composition Trend (2017–2025)
This chart illustrates how Raphas Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 214260 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Raphas Co. Ltd's current assets represent 47.1% of total assets in 2025, an increase from 44.3% in 2017.
- Cash Position: Cash and equivalents constituted 20.4% of total assets in 2025, up from 6.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 7.0% of total assets.
Raphas Co. Ltd Competitors by Total Assets
Key competitors of Raphas Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Raphas Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 0.88 | 5.08 |
| Quick Ratio | 0.67 | 0.77 | 4.58 |
| Cash Ratio | 0.00 | 0.02 | 0.58 |
| Working Capital | ₩-6.89 Billion | ₩-5.88 Billion | ₩24.46 Billion |
Raphas Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Raphas Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | ₩75.08 Billion |
| Market Capitalization | $50.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Raphas Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Raphas Co. Ltd's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Raphas Co. Ltd (2017–2025)
The table below shows the annual total assets of Raphas Co. Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩75.08 Billion ≈ $50.88 Million |
-1.34% |
| 2024-12-31 | ₩76.09 Billion ≈ $51.57 Million |
-24.21% |
| 2023-12-31 | ₩100.40 Billion ≈ $68.04 Million |
+4.52% |
| 2022-12-31 | ₩96.06 Billion ≈ $65.10 Million |
-1.82% |
| 2021-12-31 | ₩97.84 Billion ≈ $66.31 Million |
+63.54% |
| 2020-12-31 | ₩59.83 Billion ≈ $40.54 Million |
-4.86% |
| 2019-12-31 | ₩62.88 Billion ≈ $42.62 Million |
+82.20% |
| 2018-12-31 | ₩34.51 Billion ≈ $23.39 Million |
-0.86% |
| 2017-12-31 | ₩34.81 Billion ≈ $23.59 Million |
-- |
About Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more